[Form 4] NeuroPace Inc Insider Trading Activity

Rhea-AI Filing Summary

NeuroPace Inc. (NPCE) Form 4: Director Joseph Lacob was issued 1,131 shares of NeuroPace common stock on 09/19/2025 at a price of $9.94 per share under the company's non-employee director compensation policy in lieu of quarterly retainer fees. After the issuance, Mr. Lacob directly beneficially owns 13,211 shares and holds additional indirect holdings of 128,174 shares through Lacob Ventures LLC and 223,554 shares through LCT18 Investments, as disclosed on the Form 4. The filing was signed by an attorney-in-fact on 09/22/2025.

Insights

Corporate Governance Expert

TL;DR: Director received equity in lieu of cash; disclosure updates director's direct and indirect holdings.

The Form 4 documents a routine equity issuance to a non-employee director under the issuer's compensation policy. The issuance of 1,131 shares at $9.94 each represents stock-based compensation rather than a market purchase, which aligns board interests with shareholders. The filing clarifies total ownership: 13,211 shares directly and material indirect holdings through two entities. This disclosure is standard governance practice and improves transparency about insider ownership.

Securities Analyst

TL;DR: Insider compensation transaction disclosed; no derivative or sale activity reported.

Transaction code indicates acquisition (A) of non-derivative common stock as director compensation. There are no reported disposals or derivative transactions on this Form 4. The filing specifies the acquisition price per share ($9.94) and updates beneficial ownership figures across direct and indirect holdings, allowing investors to quantify insider stake but not signaling a change in control or material financing event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LACOB JOSEPH

(Last) (First) (Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		A		1,131(1)	A	$9.94	13,211	D
Common Stock								128,174	I	See footnote(2)
Common Stock								223,554	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

2. Shares are held by Lacob Ventures LLC.

3. Shares are held by LCT18 Investments.

	/s/ Leah Akin, Attorney-in-Fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Joseph Lacob report on the NPCE Form 4?

The Form 4 reports an acquisition of 1,131 shares of NeuroPace common stock on 09/19/2025 classified as director compensation.

At what price were the shares issued to the director?

The shares were issued at a reported price of $9.94 per share.

How many NeuroPace (NPCE) shares does Joseph Lacob beneficially own after the transaction?

Following the transaction, Mr. Lacob directly beneficially owns 13,211 shares, plus 128,174 shares held by Lacob Ventures LLC and 223,554 shares held by LCT18 Investments.

Was the Form 4 signed and when?

The filing bears a signature by an attorney-in-fact, /s/ Leah Akin, dated 09/22/2025.

Does the Form 4 report any derivative transactions or dispositions?

No. Table II for derivative securities shows no reported acquisitions or dispositions, and the filing reports no disposals of shares.